Lundbeck Head of R&D denies allergy aspirations

Lundbeck's recently initiated recruitment of grass allergy sufferers for a phase I trial does not herald changing winds at the pharmaceutical firm – no allergy market conquest is in the cards, says Head of R&D at Lundbeck Johan Luthman.
Lundbeck's headquarters in Denmark | Photo: Lundbeck / PR
Lundbeck's headquarters in Denmark | Photo: Lundbeck / PR
by albert rønning-andersson, translated by daniel pedersen

It created ripples when it was recently uncovered that pharmaceutical firm Lundbeck is on the lookout for 36 grass allergy sufferers for a phase I study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading